# Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

> **NCT03803605** · PHASE1 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 15 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **BIOLOGICAL:** VRC07-523LS
- **DRUG:** Vorinostat (VOR)

## Key facts

- **NCT ID:** NCT03803605
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2021-01-28
- **Final completion:** 2021-01-28
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803605, "Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03803605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*